Journal: Drug Design, Development and Therapy

Article Title: MicroRNA-339 inhibits human hepatocellular carcinoma proliferation and invasion via targeting ZNF689

doi: 10.2147/DDDT.S186352

Figure Lengend Snippet: miR-339 directly targets ZNF689 expression. Notes: ( A ) miR-339 and its presumptive binding sites in the 3′-UTR of ZNF689. Mutations were generated in the complementary site which binds to the seed region of miR-339. ( B ) miR-339 mimic and luciferase plasmids which include WT ZNF689 3′-UTR or Mut ZNF689-3′-UTR were co-transfected into HCCLM3 cells. The relative luciferase activity was determined. ( C ) The mRNA level of ZNF689 was measured by using qPCR after miR-339 mimic was transfected into HCCLM3 cells. ( D ) The protein expression of ZNF689 was detected by using Western blotting after miR-339 mimic was transfected into HCCLM3 cells. ( E ) Data represent the relative protein expression, shown as mean ± SD, n=3. * P <0.05, ** P <0.01 vs the scramble group. Abbreviations: Mut, mutant type; qPCR, quantitative PCR; WT, wild type.

Article Snippet: The primary antibody ZNF689 (1:2,000) was obtained from Novus Biologicals.

Techniques: Expressing, Binding Assay, Generated, Luciferase, Transfection, Activity Assay, Western Blot, Mutagenesis, Real-time Polymerase Chain Reaction

Journal: Drug Design, Development and Therapy

Article Title: MicroRNA-339 inhibits human hepatocellular carcinoma proliferation and invasion via targeting ZNF689

doi: 10.2147/DDDT.S186352

Figure Lengend Snippet: ZNF689 is upregulated in HCC tissues. Notes: ( A ) The mRNA level of ZNF689 in the 20 paired HCC tissues and adjacent non-tumor tissues was measured by using qPCR. ( B ) The mRNA expression of ZNF689 was significantly higher in the HCC tissues than in adjacent non-tumor tissues. ( C ) The relationship between miR-339 and ZNF689 expression was analyzed by using GraphPad Prism 5.0 software. Data are shown as mean ± SD. *** P <0.001 vs the normal tissue group. Abbreviations: HCC, hepatocellular carcinoma; qPCR, quantitative PCR.

Article Snippet: The primary antibody ZNF689 (1:2,000) was obtained from Novus Biologicals.

Techniques: Expressing, Software, Real-time Polymerase Chain Reaction

Journal: Drug Design, Development and Therapy

Article Title: MicroRNA-339 inhibits human hepatocellular carcinoma proliferation and invasion via targeting ZNF689

doi: 10.2147/DDDT.S186352

Figure Lengend Snippet: Overexpression of ZNF689 antagonizes miR-339 inhibitory effect on HCCLM3 cells. Notes: ( A ) ZNF689 mRNA expression in the HCC cell lines (HepG2, Hep3B, Bel7402 and HCCLM3) and the human normal liver cell LO2 was determined by using qPCR. ( B ) The mRNA expression of ZNF689 in HCCLM3 cells transfected with ZNF689 overexpression plasmid was measured by using qPCR. ( C ) The protein level of ZNF689 in HCCLM3 cells transfected with ZNF689 overexpression plasmid was measured by using Western blotting. ( D ) Data represent the relative protein expression. ( E – G ) ZNF689 overexpression plasmid was co-transfected with miR-339 mimic into HCCLM3 cells. ( E ) The cell proliferation was measured by using MTT. ( F ) Apoptotic cells were determined by using Annexin V-FITC/PI Apoptosis Detection Kit. ( G ) The cell invasive capacity was measured by using Transwell. 200× magnification. ( H ) The relative amount of invasive cells was analyzed with GraphPad Prism 5.0. Data are presented as mean ± SD, n=3. * P <0.05, ** P <0.01 and *** P <0.001 vs the scramble group. # P <0.05 and ### P <0.001 vs the miR-339 mimic group. Abbreviations: FITC, fluorescein isothiocyanate; HCC, hepatocellular carcinoma; PI, propidium iodide; qPCR, quantitative PCR.

Article Snippet: The primary antibody ZNF689 (1:2,000) was obtained from Novus Biologicals.

Techniques: Over Expression, Expressing, Transfection, Plasmid Preparation, Western Blot, Real-time Polymerase Chain Reaction

Journal: Drug Design, Development and Therapy

Article Title: MicroRNA-339 inhibits human hepatocellular carcinoma proliferation and invasion via targeting ZNF689

doi: 10.2147/DDDT.S186352

Figure Lengend Snippet: Primer sequences used in qPCR assay

Article Snippet: The primary antibody ZNF689 (1:2,000) was obtained from Novus Biologicals.

Techniques:

Journal: Gut Microbes

Article Title: A dietary carbohydrate – gut Parasutterella – human fatty acid biosynthesis metabolic axis in obesity and type 2 diabetes

doi: 10.1080/19490976.2022.2057778

Figure Lengend Snippet: Parasutterella and obesity, glucose and lipid abnormalities as well as metabolic inflammation . (a) Association of Parasutterella sp . with weight and BMI in n = 1,544 subjects reported through estimate and standard error (Hurdle count model). (b) Association of Parasutterella sp. with metabolic parameter in n = 1,544 subjects reported through estimate and standard error (Hurdle count model). (c) Association of Parasutterella sp. with diabetes in n = 1,544 subjects reported through estimate and standard error (Hurdle count model). (d) Association of Parasutterella sp. with inflammatory parameters in n = 1,544 subjects reported through estimate and standard error (Hurdle count model). (e) Parasutterella sp. abundance in relation to BMI and T2D groups in the FoCus cohort. (f) Parasutterella sp. abundance in relation to BMI and T2D groups in the ATP cohort. While the sequencing depth of the ATP cohort was slightly lower overall than in FoCus (median FoCus: 36,048; median ATP: 22,931), Figures 1e and f demonstrate that the distribution of Parasutterella abundance in relation to BMI is comparable in both cohorts and that Parasutterella is a highly abundant microbe in ATP as well, although the height of box plots differs slightly between cohorts.

Article Snippet: For qPCR, a tenfold serial dilution of Parasutterella excrementihominis was generated to produce a standard curve (ordered from DSMZ, Germany).

Techniques: Sequencing

Journal: Gut Microbes

Article Title: A dietary carbohydrate – gut Parasutterella – human fatty acid biosynthesis metabolic axis in obesity and type 2 diabetes

doi: 10.1080/19490976.2022.2057778

Figure Lengend Snippet: Dietary parameters regarding the abundance of Parasutterella sp. (two-part Hurdle model), truncated linear model considering only counts of Parasutterella sp. (count part). Dependencies of parameters and the abundance of Parasutterella sp. reported through estimate, confidence intervals, and p-values in the respective model. First part of the Hurdle model considers only counts of Parasutterella sp. using a negative binomial regression. After FDR-correction, p-values were not significant

Article Snippet: For qPCR, a tenfold serial dilution of Parasutterella excrementihominis was generated to produce a standard curve (ordered from DSMZ, Germany).

Techniques:

Journal: Gut Microbes

Article Title: A dietary carbohydrate – gut Parasutterella – human fatty acid biosynthesis metabolic axis in obesity and type 2 diabetes

doi: 10.1080/19490976.2022.2057778

Figure Lengend Snippet: Parasutterella and gut microbiome diversity measures. Beta diversity was assessed by Bray-Curtis distance and PERMANOVA. Alpha diversity was assessed by species richness, Chao1 Index and Shannon Index. Statistical significance between high and low Parasutterella groups was tested by Wilcoxon tests.

Article Snippet: For qPCR, a tenfold serial dilution of Parasutterella excrementihominis was generated to produce a standard curve (ordered from DSMZ, Germany).

Techniques:

Journal: Gut Microbes

Article Title: A dietary carbohydrate – gut Parasutterella – human fatty acid biosynthesis metabolic axis in obesity and type 2 diabetes

doi: 10.1080/19490976.2022.2057778

Figure Lengend Snippet: Parasutterella in relation to other gut microbiome species in human obesity . (a) LogFold Changes of differentially abundant microbes in human obesity in the FoCus cohort. Comparison was made between the normal weight group (BMI < 25) and the obese group (BMI > 30, without T2D). Parasutterella sp . is among the top 20 (=3%) differentially abundant species out of 665 species tested. Plot shows the top 50 differentially expressed species, eight species could not be assigned to a genus (marked NA in the plot). Parasutterella sp . is placed 18th among the top 50. (b) Composition plots of probands with high and low (threshold <10 counts) Parasutterella sp . (c) ROC curves for prediction models (random forests) of BMI and T2D groups by Akkermansia (green, AUC: 0.22–0.28) and Parasutterella (purple, AUC: 0.83–0.87) abundance. Comparisons were made between the normal weight group and the (1) obese group without diabetes, (2) obese group with diabetes, and (3) the overweight group according to . Classifier performance was tested using bootstrapping of AUC results and revealed significantly better performance of Parasutterella compared to Akkermansia in all comparison groups ( P = 5.2e-191;-2.8e-185).

Article Snippet: For qPCR, a tenfold serial dilution of Parasutterella excrementihominis was generated to produce a standard curve (ordered from DSMZ, Germany).

Techniques: Comparison

Journal: Gut Microbes

Article Title: A dietary carbohydrate – gut Parasutterella – human fatty acid biosynthesis metabolic axis in obesity and type 2 diabetes

doi: 10.1080/19490976.2022.2057778

Figure Lengend Snippet: Metabolomic parameters regarding the abundance of Parasutterella sp . (two-part Hurdle model) showing negative associations by using a truncated linear model considering only counts of Parasutterella sp . (count part). Dependencies of parameters and the abundance of Parasutterella sp . reported through estimate, confidence intervals, and FDR- adjusted p-values in the respective model. First part of the Hurdle model considers only counts of Parasutterella sp . using a negative binomial regression. Parameters are chosen considering the five highest estimates

Article Snippet: For qPCR, a tenfold serial dilution of Parasutterella excrementihominis was generated to produce a standard curve (ordered from DSMZ, Germany).

Techniques:

Journal: Gut Microbes

Article Title: A dietary carbohydrate – gut Parasutterella – human fatty acid biosynthesis metabolic axis in obesity and type 2 diabetes

doi: 10.1080/19490976.2022.2057778

Figure Lengend Snippet: Metabolomic parameters regarding the abundance of Parasutterella sp . (two-part Hurdle model) showing positive associations by using a truncated linear model considering only counts of Parasutterella sp . (count part). Dependencies of parameters and the abundance of Parasutterella sp . reported through estimate, confidence intervals, and BH- adjusted p-values in the respective model. First part of the Hurdle model considers only counts of Parasutterella sp . using a negative binomial regression. Parameters are chosen considering the five highest estimates

Article Snippet: For qPCR, a tenfold serial dilution of Parasutterella excrementihominis was generated to produce a standard curve (ordered from DSMZ, Germany).

Techniques:

Journal: Gut Microbes

Article Title: A dietary carbohydrate – gut Parasutterella – human fatty acid biosynthesis metabolic axis in obesity and type 2 diabetes

doi: 10.1080/19490976.2022.2057778

Figure Lengend Snippet: Parasutterella and metabolic pathway enrichment analysis.

Article Snippet: For qPCR, a tenfold serial dilution of Parasutterella excrementihominis was generated to produce a standard curve (ordered from DSMZ, Germany).

Techniques:

Journal: Gut Microbes

Article Title: A dietary carbohydrate – gut Parasutterella – human fatty acid biosynthesis metabolic axis in obesity and type 2 diabetes

doi: 10.1080/19490976.2022.2057778

Figure Lengend Snippet: Parasutterella and human weight loss intervention . (a) Difference of BMI in subjects of intervention at baseline compared with 12 weeks (Wilcoxon signed-rank test, P < .05), (n = 55). (b) Abundance of Parasutterella excrementihominis in subjects of intervention at baseline compared with 12 weeks (Wilcoxon signed-rank test, P < .05), (n = 55).

Article Snippet: For qPCR, a tenfold serial dilution of Parasutterella excrementihominis was generated to produce a standard curve (ordered from DSMZ, Germany).

Techniques:

Journal: Gut Microbes

Article Title: A dietary carbohydrate – gut Parasutterella – human fatty acid biosynthesis metabolic axis in obesity and type 2 diabetes

doi: 10.1080/19490976.2022.2057778

Figure Lengend Snippet: Summary figure on the proposed dietary Carbohydrate – Gut Parasutterella – Human Fatty Acid Biosynthesis metabolic axis.

Article Snippet: For qPCR, a tenfold serial dilution of Parasutterella excrementihominis was generated to produce a standard curve (ordered from DSMZ, Germany).

Techniques:

Journal: OncoTargets and therapy

Article Title: Dynamic Changes in Serum Markers and Their Utility in the Early Diagnosis of All Stages of Hepatitis B-Associated Hepatocellular Carcinoma

doi: 10.2147/OTT.S229835

Figure Lengend Snippet: The Clinicopathological Characteristics of the Study Population

Article Snippet: The following antibodies were spotted on aldehyde-coated microscope slides (Shanghai Baiao, China) by a GeSiM Nano-Plotter TM Micropipetting System (Radeberg, Germany): mouse monoclonal AFP antibody (1.25 mg/mL, Frpon Botech Inc, Shenzhen, China), mouse monoclonal GPC3 antibody (1 mg/mL, R&D Bio-techne, Minneapolis, USA), mouse monoclonal Golgi membrane protein 1 (GOLM1) antibody (0.5 mg/mL, Novus, Centennial, USA) and mouse monoclonal prothrombin factor II antibody (2.5mg/mL, Fujirebio Inc, Tokyo, Japan).

Techniques:

Journal: OncoTargets and therapy

Article Title: Dynamic Changes in Serum Markers and Their Utility in the Early Diagnosis of All Stages of Hepatitis B-Associated Hepatocellular Carcinoma

doi: 10.2147/OTT.S229835

Figure Lengend Snippet: The levels of serum AFP, GPC3, GP73 and DCP in each subgroup. ( A ) AFP. ( B ) GPC3. ( C ) GP73. ( D ) DCP. ( E ) Representative image of each subgroup. * P <0.05, ** P <0.01. Abbreviations: HCC, hepatocellular carcinoma; LC, liver cirrhosis; CHB, chronic hepatitis B virus infection; HC, healthy controls; AFP, α-fetoprotein; GPC3, glypican 3; GP73, golgi protein 73; DCP, des-γ-carboxy prothrombin; ns, no significance; int, intensity.

Article Snippet: The following antibodies were spotted on aldehyde-coated microscope slides (Shanghai Baiao, China) by a GeSiM Nano-Plotter TM Micropipetting System (Radeberg, Germany): mouse monoclonal AFP antibody (1.25 mg/mL, Frpon Botech Inc, Shenzhen, China), mouse monoclonal GPC3 antibody (1 mg/mL, R&D Bio-techne, Minneapolis, USA), mouse monoclonal Golgi membrane protein 1 (GOLM1) antibody (0.5 mg/mL, Novus, Centennial, USA) and mouse monoclonal prothrombin factor II antibody (2.5mg/mL, Fujirebio Inc, Tokyo, Japan).

Techniques: Virus, Infection

Journal: OncoTargets and therapy

Article Title: Dynamic Changes in Serum Markers and Their Utility in the Early Diagnosis of All Stages of Hepatitis B-Associated Hepatocellular Carcinoma

doi: 10.2147/OTT.S229835

Figure Lengend Snippet: The Value of Serum AFP, GPC3, GP73 and DCP in the Diagnosis of HCC (Including All HCC Patients)

Article Snippet: The following antibodies were spotted on aldehyde-coated microscope slides (Shanghai Baiao, China) by a GeSiM Nano-Plotter TM Micropipetting System (Radeberg, Germany): mouse monoclonal AFP antibody (1.25 mg/mL, Frpon Botech Inc, Shenzhen, China), mouse monoclonal GPC3 antibody (1 mg/mL, R&D Bio-techne, Minneapolis, USA), mouse monoclonal Golgi membrane protein 1 (GOLM1) antibody (0.5 mg/mL, Novus, Centennial, USA) and mouse monoclonal prothrombin factor II antibody (2.5mg/mL, Fujirebio Inc, Tokyo, Japan).

Techniques:

Journal: OncoTargets and therapy

Article Title: Dynamic Changes in Serum Markers and Their Utility in the Early Diagnosis of All Stages of Hepatitis B-Associated Hepatocellular Carcinoma

doi: 10.2147/OTT.S229835

Figure Lengend Snippet: Assessment of the diagnostic value of serum AFP, GPC3, GP73 and DCP in differentiating HBV-related HCC from controls. ( A ) All HCC vs LC, CHB, HC. ( B ) All HCC vs LC, CHB. ( C ) All HCC v s LC. ( D ) Very early and early stage HCC vs LC, CHB, HC. ( E ) Very early and early stage HCC vs LC, CHB. ( F ) Very early and early stage HCC vs LC. Abbreviations: HCC, hepatocellular carcinoma; LC, liver cirrhosis; CHB, chronic hepatitis B virus infection; HC, healthy controls; AFP, α-fetoprotein; GPC3, glypican 3; GP73, golgi protein 73; DCP, des-γ-carboxy prothrombin.

Article Snippet: The following antibodies were spotted on aldehyde-coated microscope slides (Shanghai Baiao, China) by a GeSiM Nano-Plotter TM Micropipetting System (Radeberg, Germany): mouse monoclonal AFP antibody (1.25 mg/mL, Frpon Botech Inc, Shenzhen, China), mouse monoclonal GPC3 antibody (1 mg/mL, R&D Bio-techne, Minneapolis, USA), mouse monoclonal Golgi membrane protein 1 (GOLM1) antibody (0.5 mg/mL, Novus, Centennial, USA) and mouse monoclonal prothrombin factor II antibody (2.5mg/mL, Fujirebio Inc, Tokyo, Japan).

Techniques: Diagnostic Assay, Virus, Infection

Journal: OncoTargets and therapy

Article Title: Dynamic Changes in Serum Markers and Their Utility in the Early Diagnosis of All Stages of Hepatitis B-Associated Hepatocellular Carcinoma

doi: 10.2147/OTT.S229835

Figure Lengend Snippet: The Value of Serum AFP, GPC3, GP73 and DCP in the Early Diagnosis of HCC (Including the Very Early HCC)

Article Snippet: The following antibodies were spotted on aldehyde-coated microscope slides (Shanghai Baiao, China) by a GeSiM Nano-Plotter TM Micropipetting System (Radeberg, Germany): mouse monoclonal AFP antibody (1.25 mg/mL, Frpon Botech Inc, Shenzhen, China), mouse monoclonal GPC3 antibody (1 mg/mL, R&D Bio-techne, Minneapolis, USA), mouse monoclonal Golgi membrane protein 1 (GOLM1) antibody (0.5 mg/mL, Novus, Centennial, USA) and mouse monoclonal prothrombin factor II antibody (2.5mg/mL, Fujirebio Inc, Tokyo, Japan).

Techniques:

Journal: OncoTargets and therapy

Article Title: Dynamic Changes in Serum Markers and Their Utility in the Early Diagnosis of All Stages of Hepatitis B-Associated Hepatocellular Carcinoma

doi: 10.2147/OTT.S229835

Figure Lengend Snippet: The Value of Serum AFP, GPC3, GP73 and DCP in the Very Early Diagnosis of HCC

Article Snippet: The following antibodies were spotted on aldehyde-coated microscope slides (Shanghai Baiao, China) by a GeSiM Nano-Plotter TM Micropipetting System (Radeberg, Germany): mouse monoclonal AFP antibody (1.25 mg/mL, Frpon Botech Inc, Shenzhen, China), mouse monoclonal GPC3 antibody (1 mg/mL, R&D Bio-techne, Minneapolis, USA), mouse monoclonal Golgi membrane protein 1 (GOLM1) antibody (0.5 mg/mL, Novus, Centennial, USA) and mouse monoclonal prothrombin factor II antibody (2.5mg/mL, Fujirebio Inc, Tokyo, Japan).

Techniques:

Journal: OncoTargets and therapy

Article Title: Dynamic Changes in Serum Markers and Their Utility in the Early Diagnosis of All Stages of Hepatitis B-Associated Hepatocellular Carcinoma

doi: 10.2147/OTT.S229835

Figure Lengend Snippet: The value of serum AFP, GPC3, GP73 and DCP in the very early diagnosis of HBV-related HCC. ( A ) Very early stage HCC vs LC, CHB, HC. ( B ) Very early stage vs LC, CHB. ( C ) Very early stage vs LC. Abbreviations: HCC, hepatocellular carcinoma; LC, liver cirrhosis; CHB, chronic hepatitis B virus infection; HC, healthy controls; AFP, α-fetoprotein; GPC3, glypican 3; GP73, golgi protein 73; DCP, des-γ-carboxy prothrombin.

Article Snippet: The following antibodies were spotted on aldehyde-coated microscope slides (Shanghai Baiao, China) by a GeSiM Nano-Plotter TM Micropipetting System (Radeberg, Germany): mouse monoclonal AFP antibody (1.25 mg/mL, Frpon Botech Inc, Shenzhen, China), mouse monoclonal GPC3 antibody (1 mg/mL, R&D Bio-techne, Minneapolis, USA), mouse monoclonal Golgi membrane protein 1 (GOLM1) antibody (0.5 mg/mL, Novus, Centennial, USA) and mouse monoclonal prothrombin factor II antibody (2.5mg/mL, Fujirebio Inc, Tokyo, Japan).

Techniques: Virus, Infection